Merck's Pulmonary Arterial Hypertension Drug Meets Primary Endpoint

Published: 2025-06-23 09:22:15 ET MRK

Published on 06/23/2025 at 09:22

By Adriano Marchese

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

On Monday, the pharmaceutical company said it has received positive topline results from the Phase 3 Hyperion study evaluating Winrevair, also known as sotatercept-csrk, in recently diagnosed adults with pulmonary arterial hypertension, or PAH.

PAH is a condition where the small arteries found in the lungs become narrowed or blocked, constricting blood flow through them and can lead to high blood pressure in the pulmonary arteries that supply the lungs.

The study found that using the therapy showed a statistically significant and clinically meaningful reduction in the risk of clinical worsening events when compared to placebo.

Write to Adriano Marchese at [email protected]

(END) Dow Jones Newswires

06-23-25 0921ET